AstraZeneca colon cancer drug fails test

Category Business, Health | Monday, March 8th, 2010

AstraZeneca PLC said Monday that its cancer drug Recentin failed in a head to head late stage trial with Roche AG’s Avastin in tests for use as an initial treatment against colon cancer.

The London-based drug company said it will wait for the results of a second study on Recentin — this time testing its effectiveness in combination with chemotherapy compared with chemotherapy alone — before deciding whether to submit the drug to regulators for marketing approval.

Related Amazon.com

Keyword: Astra, Astra colon cancer, Astra colon cancer drug, Astrazeneca, Astrazeneca Plc, Avastin, cancer, Cancer Drug, Chemotherapy, colon, Colon Cancer, colon cancer drug, colon cancers, Drug Test, Initial Treatment, London Drug, Marketing, Regulators, Roche, Roche AG, Stage Trial